|Year : 2009 | Volume
| Issue : 5 | Page : 540-544
Department of Dermatology; SMIMER, Surat-395010; Gujarat, India
|Date of Web Publication||3-Sep-2009|
Department of Dermatology, Room No -10, Smimer Hospital, Opp. Bombay Market, Umarwada, Surat -10, Gujarat
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Vaishnani J. Superantigen. Indian J Dermatol Venereol Leprol 2009;75:540-4
| Introduction|| |
Kappler et al .  describe a family of microbial proteins termed 'Superantigen' (SAg) that stimulates strong T-cell receptor (TCR) Vb restricted response. Superantigens are among the most potent T-cell mitogen known, with characteristic Vb signature. Previously SAg concept was limited to T cell only but recently the concept of B-cell SAg is growing. Besides classical SAg-mediated disease e.g. toxic shock syndrome (TSS), SAgs have also been proposed to contribute to the pathogenesis of several poorly understood acute and chronic inflammatory conditions including rheumatoid arthritis and psoriasis. Superantigens are not only powerful tools for the study of immunological phenomenon, but also its use is implicated in therapeutic intervention.
| Definition|| |
Superantigens are microbial proteins of 22-29 Daltons in size and are potent stimulators of the immune cells in a unconventional manner produced by bacteria, virus and mycoplasma. It has two domain folding comprising of the NH 2 terminal β barrel providing the binding region for the MHC-II receptor and α long COOH terminal a barrel providing the binding site for Vβ region of TCR [Table 1].
| T-Cell and B-Cell Receptors|| |
T-cell receptor (TCR) comprises of two peptide chains, either α/β or γ/δ, non-covalently associated with CD3γδε and ζ chains. , Ninety percent of peripheral blood T cells have α/β peptide chain, while γ/δ chain is present on 4% (range 1-10%) of peripheral blood and lymph node lymphocytes and 1% of thymocytes.
α Peptide chain contains three regions V (variable), J (junctional) and C (constant), while β peptide chain in addition has a fourth region D (diversity). Each TCR complex (α/β chain) constant region interacts with CD3γδε and ζ chains and consists of immunoglobulin like, connecting peptide, transmembrane and cytoplasmic domain [Figure 1].
B-cell receptors (BCRs) comprise of membrane-bound immunoglobulin (Ig) on the surface. The C region of Ig remains inserted in the membrane of B cell, while the V region acts as the antigen-binding site (Fab). For any given Ig molecule the V region differs from every other immunoglobulin (Ig). Sequence variability is found in three segments of V region, designated as hyper-variable regions e.g. V1, V2, V3, and identified in both heavy (VH) and light (VL). The most variable part of the region V is VH3 [Figure 2].
In classical response, after antigen processing by antigen presenting cell (APC), an epitope from a protein antigen acts as a bridge between the HLA complex of APC and TCR. , Only a small proportion of T cells become activated particularly after a co-stimulatory signal is produced by the APC. Response is highly regulated in order to limit harmful effects [Figure 3].
T cell SAg binds directly to TCR and MHC-II receptor outside the conventional antigen-binding site, thus bypassing the restrictive feature of conventional antigen processing. , Superantigen binds to Vβ domain of TCR, where Vβ refers to a variable region of b peptide. Different SAgs have specificity for one or limited sets of Vβ designation. SAg can stimulate all T cells bearing the particular Vβ designation, thus SAg can stimulate 20-30% of the total T lymphocytes in an individual [Figure 3].
MHC-II positive cells are required for SAg-induced T-cell activation, but it is not MHC-II restrictive, and binding of MHC-II receptor determines the susceptibility of an individual to the particular SAg.
Besides Vβ-specific T-cell activation, certain SAgs, e.g. SEH (Staphylococcal Enterotoxin H) induces Vα-specific T-cell activation. In case of MAM (mycoplasma arthritidis associated Superantigen), interaction is intermediate between SAg and conventional peptide antigen.
B cell SAg  interacts with the variable region of heavy/light chain outside the conventional antigen-binding site, thus activating B cells in a VH selective manner. Most B-cell SAgs bind to the heavy chain from VH3 gene family. VH3 gene family is the largest of the seven human VH gene families and expressed by 30−60% of peripheral B cells [Table 2].
| Superantigen Interaction and its Effects|| |
As there is no definite disease model for SAg-mediated disease, many in vivo and in vitro studies demonstrate various effects of SAg.
Massive T-cell activation and release of cytokines, e.g. TNF-α, IL-2, IL-6, INF-γ in large amount, results in capillary leak and systemic shock. There is a biphasic response after SAg stimulation of T cell, with a T-cell derived initial peak of IL-2, TNF-α, followed by second peak from macrophage-derived cytokines. Proliferation of Vb-specific T cell, but not an antigen restrictive.
Deletion:  Initially Vβ-specific T-cells expansion followed by Vβ-specific clonal deletion of T cells.
Anergy:  Hyporesponsive state of T cell to an antigen in the absence of appropriate co-stimulatory signal.
T-cell dependent B-cell activation characterized by polyclonal IgM and IgG production, enhances humoral immunity via Ag-specific CD4 + T cells 
Cytotoxicity: (1) Cyctotoxic T-cell mediated cytotoxicity against MHC class II positive cells, known as SAg-dependent cell-mediated cytotoxicity (SDCC). (2) Activation-induced cell death (AICD). (3) Superantigen-dependent autokilling. 
Induction of autoimmune status: , Although there are no direct evidences for this SAg has been proposed as one of the etiologies for autoimmune disease. Autoimmune state may result from indiscriminate Vb-specific expansion that amplifies the clone that manifests cross reactivity towards endogenous antigen and loss of self-tolerance. This may persist even after original SAg stimuli ceases. Three different mechanisms have been proposed for induction of autoimmune status (1) In presence of SAgs and multivalent autoantigen abnormal Th-B cell interactions lead to activation, proliferation and differentiation of B-cells and production of autoantibody. (2) T-cell independent and direct activation of B cell by SAgs. (3) Superantigens may activate resting T cells that recognize autoantigens and may remain in active state in the presence of autoantigen.
Superantigens increase the expression of glucocorticoid receptor β and are associated with decreased corticosteroid response. 
Other effects: , Stimulates lymphocyte locomotion and neutrophilic recruitment to the site of infection, emesis and augmentation of endotoxin activity. Recruitment of T cells, B cells and APCs at the site of infection, and activation of B cells and APCs further augment the cytokine release.
| B-Cell Superantigen|| |
B-cell SAg binds to serum Igs and leads to the formation of large amount of immune complexes. Such immune complexes activate the complement pathway and inflict tissue injury. ,
B-cell SAgs bind to the surface Igs on mast cells and basophils, resulting in the release of pro-inflammatory mediators. T-cell independent VH-specific B-cell activation and proliferation, followed by clonal deletion, and prolonged suppression of antibody production.
| Endogenous Superantigens|| |
Endogenous Superantigens (ESAgs) are cell membrane proteins encoded by certain viruses that infect mammalian cells.  In humans ESAg is encoded by env gene of human endogenous retrovirus (HERV), and all humans carry numerous copies of HERV in their genome. Exact significance of ESAg is not known in humans. Endogenous superantigen stimulates T cell in Vβ in a selective manner to support viral replication and plays a role in the pathogenesis of EB virus infections, HIV infection, CMV infection and IDDM (Insulin Dependent Diabetes Mellitus).
| Treatment Strategies for Superantigen -Mediated Disease|| |
As there is no definite disease model for SAg-mediated disease and lack of controlled trials about therapeutic intervention, many drugs are claimed to be effective with different immunological properties. Following treatment strategies are proposed for the diseases associated with SAg.
- Removal of source of SAg
- Drain the abscess
- Early and adequate antibacterial therapy, e.g. Clindamycin
- Supportive care for shock
- Immunomodulatory drugs:
Drugs useful for various SAg-associated diseases are shown in [Table 3].
[Table 4] gives superantigen toxins, and [Table 5] diseases thought to be mediated by superantigen, and [Table 6] factors affecting SAg-induced response.
| References|| |
|1.||Kappler J, Kotzin B, Herron L, Gelfand EW, Bigler RD, Boylston A, Carrel S, Posnett DN, Choi Y, Marrack P. V beta-specific stimulation of human T cells by staphylococcal toxins. Science 1989;244:811-3. [PUBMED] [FULLTEXT]|
|2.||Parish WE, Breathnach SM. Clinical Immunology and Allergy. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Rook Textbook of dermatology. 6 th edition. Oxford: Blackwell Science 1998. p. 277-36. |
|3.||Janeway CA, Travers P, Walport M, Shlomchik MJ, editors. Antigen recognition by B cell and T cell receptors. In: Immunobiology, The immune system in health and disease; 5 th edition. London: Garland Publishing: 2001. p. 93-122. |
|4.||Choi Y, Lafferty JA, Clements JR, Todd JK, Gelfand EW, Kappler J, Marrack P, Kotzin BL. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med 1990;172:981-4. [PUBMED] [FULLTEXT]|
|5.||Llewelyn M, Cohen J. Superantigen: Microbial agents that corrupt immunity.The lancet infectious disease 2002;2:156-62. |
|6.||Kozlowski LM, Li W, Goldschmidt M, Levinson AI. In vivo inflammatory response to a prototypic B cell superantigen: Elicitation of an arthus reaction by staphylococcal protein A. J Immunol 1998;160:5246-2. [PUBMED] [FULLTEXT]|
|7.||Bette M, Schafer MK, Rooijen VN, Weihe E and Fleischer B. Distribution and kinetics of superantigen-induced cytokine gene expression in mouse spleen. J Exp Med 1993;178:1531-9. |
|8.||Renno T, Hahne M, Tschopp J, MacDonald HR. Peripheral T Cells Undergoing Superantigen-induced Apoptosis In vivo Express B220 and Upregulate Fas and Fas ligand. J Exp Med 1996;183:431-7. [PUBMED] [FULLTEXT]|
|9.||Kawabe Y, Ochi A. Selective anergy of V b 8+, CD4Tcells in staphylococcus enterotoxin B-primed mice. J Exp Med 1990;172:1065-70. [PUBMED] [FULLTEXT]|
|10.||Torres BA, Perrin GQ, Mujtaba MG, Subramaniam PS, PS, Anderson AK, Johnson HM. Superantigen enhancement of specific immunity:antibody production and signaling pathway. J Immunol 2002;169:2907-4. [PUBMED] [FULLTEXT]|
|11.||Holzer U, Orlikowsky T, Zehrer C, Bethge W, Dohlsten M, Kalland T; et al . T-cell stimulation and cytokines release induced by staphylococcal enterotoxin A (SEA) and SEAD227A mutant. Immunol 1997;90:74-80. |
|12.||Tchilian EZ, Anderson G, Moore NC, Owen JJ, Jenkinson EJ. Involvement of LFA/ICAM-2 adhesive interaction and PKC in activation induced cell death following SEB rechallange. J Immunol 1996;87:566-72. |
|13.||Koning F, Rust C. Staphylococcal enterotoxin mediated human T-T cell interaction. J Immunol 1992;149:317-2. [PUBMED] [FULLTEXT]|
|14.||Friedman SM, Posnett DN, Tumang JR, Cole BC, Crow MK. A potential role for microbial superantigens in the pathogenesis of systemic autoimmune disease. Arthritis Rheum 1991;34:468-80. [PUBMED] |
|15.||Crow MK. Connective tissue disorders-systemic lupus erythematosus, cellular immunology. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH editors. Rheumatology 3 rd edition. Philadelphia: MOSBY (Elsevier Science); 2003 p.1347-1358. |
|16.||Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol 2000;105:782-7. [PUBMED] [FULLTEXT]|
|17.||Anderson AL, Sporici R, Lambris J, Larosa D, Levision AI. Pathogenesis of B cell Superantigen induced immune complex mediated inflammation. Infection and Immunity 2006; 74:1196-1203. |
|18.||Pousnett DN, Yarilina AA. Sleeping with enemy-Endogenous superantigen in humans. Immunity 2001;15:503-6. |
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]
|This article has been cited by|
||Exfoliative toxins of Staphylococcus aureus
| ||Bukowski, M., Wladyka, B., Dubin, G. |
| ||Toxins. 2010; 2(5): 1148-1165 |
||Exfoliative Toxins of Staphylococcus aureus
| ||Michal Bukowski,Benedykt Wladyka,Grzegorz Dubin |
| ||Toxins. 2010; 2(5): 1148 |
|[Pubmed] | [DOI]|